Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD

A Phase III trial found the donor-derived cell therapy deramiocel slowed arm muscle decline in boys and young men with advanced Duchenne muscular dystrophy, with potential benefits for heart health and a favorable safety profile.

The post Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD appeared first on GEN - Genetic Engineering and Biotechnology News.